1,327 reports of this reaction
2.2% of all DARATUMUMAB reports
#11 most reported adverse reaction
THROMBOCYTOPENIA is the #11 most commonly reported adverse reaction for DARATUMUMAB, manufactured by Janssen Biotech, Inc.. There are 1,327 FDA adverse event reports linking DARATUMUMAB to THROMBOCYTOPENIA. This represents approximately 2.2% of all 59,976 adverse event reports for this drug.
Patients taking DARATUMUMAB who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for DARATUMUMAB, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for DARATUMUMAB:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 1,327 FDA reports for DARATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.2% of all adverse event reports for DARATUMUMAB, making it a notable side effect.
If you experience thrombocytopenia while taking DARATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.